|
May 14
|
Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag
|
|
May 14
|
Allogene Therapeutics Inc (ALLO) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
|
|
May 13
|
Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates
|
|
May 13
|
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
|
|
May 13
|
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
|
|
May 10
|
CollPlant Biotechnologies (CLGN) Soars 8.2%: Is Further Upside Left in the Stock?
|
|
May 6
|
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
|
|
Apr 26
|
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
|
|
Apr 25
|
Omega Therapeutics, Inc. (OMGA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
|
Apr 24
|
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?
|
|
Apr 11
|
3 Meme Stocks to Sell and Replace With Meme Coins
|
|
Apr 9
|
Allogene Therapeutics Announces Q2 Investor Conference Participation
|
|
Mar 16
|
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcript
|
|
Mar 15
|
Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss
|
|
Mar 15
|
Q4 2023 Allogene Therapeutics Inc Earnings Call
|
|
Mar 14
|
Allogene Therapeutics Inc (ALLO) Reports Q4 and Full Year 2023 Financials, Forecasts Cash ...
|
|
Mar 14
|
Allogene Therapeutics (ALLO) Reports Q4 Loss, Lags Revenue Estimates
|
|
Mar 14
|
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
|
|
Mar 13
|
Allogene (ALLO) Inks Deal With Arbor Bio for CRISPR Technology
|
|
Mar 12
|
Allogene taps Arbor in pursuit of ‘off-the-shelf’ CAR-T therapies for autoimmune disease
|